Federated Hermes’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-31,714
Closed -$2.32M – 2090
2024
Q1
$2.32M Sell
31,714
-7,250
-19% -$535K 0.01% 893
2023
Q4
$2.78M Sell
38,964
-10,060
-21% -$594K 0.01% 864
2023
Q3
$2.94M Sell
49,024
-245
-0.5% -$16.1K 0.01% 823
2023
Q2
$3.55M Sell
49,269
-1,959
-4% -$147K 0.01% 789
2023
Q1
$3.77M Buy
51,228
+23,661
+86% +$1.68M 0.01% 775
2022
Q4
$1.84M Buy
27,567
+27,556
+250,509% +$1.79M 0.01% 937
2022
Q3
$1K Hold
11
– – ﹤0.01% 2054
2022
Q2
$1K Sell
11
-6,836
-100% -$622K ﹤0.01% 2052
2022
Q1
$770K Sell
6,847
-2,346
-26% -$273K ﹤0.01% 1334
2021
Q4
$1.42M Sell
9,193
-3
-0% -$444 ﹤0.01% 1152
2021
Q3
$1.28M Sell
9,196
-56,181
-86% -$6.97M ﹤0.01% 1191
2021
Q2
$8.58M Buy
65,377
+52,377
+403% +$6.98M 0.02% 709
2021
Q1
$1.98M Sell
13,000
-23,173
-64% -$3.51M ﹤0.01% 1109
2020
Q4
$3.6M Buy
36,173
+12,789
+55% +$1.17M 0.01% 899
2020
Q3
$2.23M Buy
23,384
+21,216
+979% +$2.32M 0.01% 950
2020
Q2
$242K Sell
2,168
-9
-0.4% -$915 ﹤0.01% 1607
2020
Q1
$158K Sell
2,177
-470
-18% -$42.7K ﹤0.01% 1601
2019
Q4
$276K Sell
2,647
-646
-20% -$69.2K ﹤0.01% 1550
2019
Q3
$328K Sell
3,293
-590
-15% -$59.4K ﹤0.01% 1507
2019
Q2
$443K Sell
3,883
-3,530
-48% -$417K ﹤0.01% 1453
2019
Q1
$932K Buy
7,413
+216
+3% +$26.2K ﹤0.01% 1333
2018
Q4
$977K Sell
7,197
-21,226
-75% -$3.63M ﹤0.01% 1294
2018
Q3
$7.8M Hold
28,423
– – 0.02% 665
2018
Q2
$13.6M Buy
65,639
+48,953
+293% +$8.76M 0.04% 351
2018
Q1
$2.76M Sell
16,686
-5,901
-26% -$935K 0.01% 836
2017
Q4
$3.09M Buy
22,587
+8,310
+58% +$1.15M 0.01% 773
2017
Q3
$1.94M Buy
+14,277
New +$1.81M 0.01% 929
2016
Q3
– Sell
-4,634
Closed -$553K – 2143
2016
Q2
$553K Buy
4,634
+4,603
+14,848% +$548K ﹤0.01% 1253
2016
Q1
$3K Buy
+31
New +$3.02K ﹤0.01% 1939
2015
Q4
– Sell
-1,455
Closed -$125K – 2123
2015
Q3
$125K Buy
1,455
+711
+96% +$69.2K ﹤0.01% 1553
2015
Q2
$75K Buy
+744
New +$65.1K ﹤0.01% 1612
2015
Q1
– Sell
-56
Closed -$3K – 2043
2014
Q4
$3K Sell
56
-25,523
-100% -$1.33M ﹤0.01% 1892
2014
Q3
$1.2M Buy
25,579
+4,509
+21% +$240K ﹤0.01% 1148
2014
Q2
$1.31M Buy
21,070
+9,756
+86% +$635K ﹤0.01% 1104
2014
Q1
$761K Buy
11,314
+10,038
+787% +$671K ﹤0.01% 1237
2013
Q4
$67K Sell
1,276
-848
-40% -$44.3K ﹤0.01% 1630
2013
Q3
$92K Sell
2,124
-1,422
-40% -$64.1K ﹤0.01% 1574
2013
Q2
$133K Hold
3,546
– – ﹤0.01% 1488

Other funds holding LGND

Federated Hermes's LGND Position: Q2 2024 in Review

Federated Hermes sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 31,714 shares — an estimated $2.32M sold.

Federated Hermes first reported a position in LGND in Q2 2013 and held it in 38 quarters. The position peaked at $13.6M in Q2 2018. 235 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Federated Hermes reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Federated Hermes sold 31,714 Ligand Pharmaceuticals shares in Q2 2024, an estimated $2.32M.
  • Federated Hermes first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 38 quarters.
  • Federated Hermes's Ligand Pharmaceuticals position peaked at $13.6M in Q2 2018.
  • 235 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.